You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Chantix Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Chantix, and when can generic versions of Chantix launch?

Chantix is a drug marketed by Pf Prism Cv and is included in one NDA.

The generic ingredient in CHANTIX is varenicline tartrate. There are twelve drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Chantix

A generic version of Chantix was approved as varenicline tartrate by PAR PHARM INC on August 11th, 2021.

  Try a Trial

Paragraph IV (Patent) Challenges for CHANTIX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CHANTIX Tablets varenicline tartrate 0.5 mg and 1 mg 021928 5 2010-05-10

US Patents and Regulatory Information for Chantix

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-002 May 10, 2006 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Chantix

See the table below for patents covering Chantix around the world.

Country Patent Number Title Estimated Expiration
Iceland 6459 ⤷  Try a Trial
China 1715280 ⤷  Try a Trial
New Zealand 528210 Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof ⤷  Try a Trial
Serbia 50814 TARTARATNE SOLI 5,8,14-TRIAZATETRACIKLO(10.3.1.02,11.04,9)- HEKSADEKA-2(11),3,5,7,9-PENTAENA (TARTARATE SALTS OF 5,8,14-TRIAZATETRACYCLO(10.3.1.02,11.04,9 )-HEXADECA-2(11)3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF) ⤷  Try a Trial
Croatia P20030910 TARTARATNE SOLI 5,8,14-TRIAZATETRACIKLO {10.3.1.0<2,11>.0<4,9>}-HEKSADEKA-2(11), 3,5,7,9-PENTAENA I PRIPADAJUĆIH FARMACEUTSKIH SPOJEVA (TARTARATE SALTS 5,8,14-TRIAZATETRACYCLO {10.3.1.02,11.04,9}-HEXADECA-2(11), 3,5,7,9-PENTAENE AND PHARMACEUTICAL COMPOSITIONS THEREOF) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for Chantix

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1044189 PA2008010,C1044189 Lithuania ⤷  Try a Trial PRODUCT NAME: VARENICLINUM TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001 - EU/1/06/360/010, 0060926
1044189 CA 2008 00031 Denmark ⤷  Try a Trial
1044189 91442 Luxembourg ⤷  Try a Trial 91442, EXPIRES: 20210926
1044189 SPC021/2008 Ireland ⤷  Try a Trial SPC021/2008: 20081105, EXPIRES: 20210925
1044189 08C0039 France ⤷  Try a Trial PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.